Indeed, the MET pathway was shown to be upregulated in KRAS-mutant lung cancer after MAPK inhibition and after treatment with KRAS inhibitors [31,32], an effect that could be enhanced by mutant MET. The gene discussed is KRAS; the disease is lung cancer.